Lista de obras -

An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma

artículo científico publicado en 2017

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

scientific article published on 11 April 2021

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

artículo científico publicado en 2015

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy ⬇️

artículo científico publicado el 25 de junio de 2012

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma ⬇️

artículo científico publicado el 5 de enero de 2012

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma ⬇️

artículo científico publicado el 4 de julio de 2013

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma ⬇️

artículo científico publicado el 1 de abril de 2011

Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

artículo científico publicado en 2020

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

artículo científico publicado en 2017

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization ⬇️

artículo científico publicado el 23 de junio de 2013

Evaluating Clinical Genome Sequence Analysis by Watson for Genomics

artículo científico publicado en 2018

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

artículo científico publicado en 2019

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2020

Gemcitabine-induced Pleuropericardial Effusion in a Patient with Pancreatic Cancer ⬇️

artículo científico publicado el 10 de julio de 2012

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer

scientific article published on 15 October 2019

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015

artículo científico publicado en 2018

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma ⬇️

artículo científico publicado el 28 de septiembre de 2012

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials

artículo científico publicado en 2019

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study

scientific article published on 07 June 2019

Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer ⬇️

artículo científico publicado el 4 de octubre de 2012

Improved survival among patients enrolled in oncology phase 1 trials in recent decades

scientific article published on 19 November 2019

Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients

artículo científico publicado en 2018

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

scientific article published on 17 May 2019

Novel endoscopic technique for tri-segment drainage in patients with unresectable hilar malignant biliary strictures (with video)

scientific article published on 10 March 2020

Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients

artículo científico publicado en 2015

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer ⬇️

artículo científico publicado el 1 de enero de 2011

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

artículo científico publicado en 2020

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

artículo científico publicado en 2019

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients ⬇️

artículo científico publicado el 26 de noviembre de 2011

Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment

artículo científico publicado en 2017

Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.

artículo científico publicado en 2017

Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy ⬇️

artículo científico publicado el 24 de julio de 2012

Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy

artículo científico

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.

artículo científico publicado en 2017

Lista de obras de

An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy ⬇️

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma ⬇️

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma ⬇️

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma ⬇️

Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization ⬇️

Evaluating Clinical Genome Sequence Analysis by Watson for Genomics

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Gemcitabine-induced Pleuropericardial Effusion in a Patient with Pancreatic Cancer ⬇️

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma ⬇️

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study

Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer ⬇️

Improved survival among patients enrolled in oncology phase 1 trials in recent decades

Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Novel endoscopic technique for tri-segment drainage in patients with unresectable hilar malignant biliary strictures (with video)

Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer ⬇️

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients ⬇️

Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment

Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.

Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy ⬇️

Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.